Dr. Tony Reiman

• 
  www.myelomacanada.ca/en/advisoryboard.htm - [Cached Version]
  Published on: 3/28/2009    Last Visited: 3/28/2009  

  Dr. Tony Reiman Saint John Regional Hospital

• 
  www.chrcrm.org/main/modules/pageworks/index.php?page=00 - [Cached Version]
  Published on: 8/1/2007    Last Visited: 10/6/2007  

  Dr Tony ReimanUniversity of Alberta
  
  Tony Reiman planned to be in Edmonton for only two years.He came to the University of Alberta in 1999 for oncology training after doing his residency in internal medicine at Dalhousie University in Halifax.Dr. Reiman and his wife found that they enjoyed Edmonton and decided to stay.
  
  As a medical oncologist at the Cross Cancer Institute, Dr. Reiman specializes in treating patients with multiple myeloma, lymphoma, and lung cancer.These are all deadly cancers, and the diagnosis for many of his patients is often discouraging."I strive to give my patients the best treatments there are," says Dr. Reiman, "but the reality is that, for some cancers, even the best treatments available are not good enough.I can't imagine devoting my life to treating patients without trying to improve things.I want to be part of the process that makes things better."
  
  This commitment drives Dr. Reiman's research.His particular interest is multiple myeloma, an incurable cancer of the plasma cells.These cells-important parts of the immune system-normally make up a very small portion of the cells in the bone marrow, where they are made.
  ...
  "Patients are crucial to my research," explains Dr. Reiman.
  ...
  "RHAMM is a starting point for me to figure out what drives the biology of multiple myeloma, what distinguishes it from normal tissue," says Dr. Reiman."In the end, it may be a protein other than RHAMM that is the key.My goal is to frame the research so that we can use the knowledge we gain in a way that helps patients."
  
  Dr. Tony Reiman is a medical oncologist at the Cross Cancer Institute and an assistant professor in the Department of Oncology at the University of Alberta.An AHFMR Clinical Investigator, he is also supported by CIHR (Canadian Institutes of Health Research), the National Cancer Institute of Canada, the Lance Armstrong Foundation, and the Alberta Cancer Board.
  
  For further information, please contact Dr Tony Reiman at (780) 432-8513 or tonyreim@cancerboard.ab.ca

• 
  BioMS MEDICAL - [Cached Version]
  Published on: 9/26/2002    Last Visited: 2/17/2003  

  The Company is collaborating on the development of the technology with Dr. Pilarski; Dr. Andrew Belch, Director of the Department of Medicine at the Cross Cancer Institute and Professor of Oncology at the University of Alberta; and Dr. Tony Reiman, Medical Oncologist at the Cross Cancer Institute.
  ...
  Dr. Reiman has published on the subject of myeloma and lymphocytes and sits on a number of medical committees.
  
  The University of Alberta previously licensed its MBP8298 peptide technology for the treatment of multiple sclerosis to BioMS Medical.The University has been ranked as one of the top Universities in North America in terms of the licensing of its technologies.
  
  "We are very pleased to have entered into another collaborative relationship with BioMS.

• 
  BioMS Medical Press Release - [Cached Version]
  Published on: 9/25/2002    Last Visited: 4/20/2007  

  The Company is collaborating on the development of the technology with Dr. Pilarski; Dr. Andrew Belch, Director of the Department of Medicine at the Cross Cancer Institute and Professor of Oncology at the University of Alberta; and Dr. Tony Reiman, Medical Oncologist at the Cross Cancer Institute.
  ...
  Dr. Reiman has published on the subject of myeloma and lymphocytes and sits on a number of medical committees.

• 
  BioMS acquires new platform technology - [Cached Version]
  Published on: 9/25/2002    Last Visited: 9/25/2002  

  The Company is collaborating on the development of the technology with Dr. Pilarski; Dr. Andrew Belch, Director of the Department of Medicine at the Cross Cancer Institute and Professor of Oncology at the University of Alberta; and Dr. Tony Reiman, Medical Oncologist at the Cross Cancer Institute.
  ...
  Dr. Reiman has published on the subject of myeloma and lymphocytes and sits on a number of medical committees.
  
  The University of Alberta previously licensed its MBP8298 peptide technology for the treatment of multiple sclerosis to BioMS Medical.The University has been ranked as one of the top Universities in North America in terms of the licensing of its technologies.
  
  "We are very pleased to have entered into another collaborative relationship with BioMS.

• 
  Canadians for Health Research - Les Canadiens pour la... - [Cached Version]
  Last Visited: 10/8/2008  

  Dr Tony Reiman University of Alberta

• 
  Canadians for Health Research - Les Canadiens pour la... - [Cached Version]
  Published on: 10/6/2007    Last Visited: 9/12/2009  

  Dr Tony Reiman University of Alberta
  
  Tony Reiman planned to be in Edmonton for only two years. He came to the University of Alberta in 1999 for oncology training after doing his residency in internal medicine at Dalhousie University in Halifax. Dr. Reiman and his wife found that they enjoyed Edmonton and decided to stay.
  
  As a medical oncologist at the Cross Cancer Institute, Dr. Reiman specializes in treating patients with multiple myeloma, lymphoma, and lung cancer. These are all deadly cancers, and the diagnosis for many of his patients is often discouraging. "I strive to give my patients the best treatments there are," says Dr. Reiman, "but the reality is that, for some cancers, even the best treatments available are not good enough. I can't imagine devoting my life to treating patients without trying to improve things. I want to be part of the process that makes things better."
  
  This commitment drives Dr. Reiman's research. His particular interest is multiple myeloma, an incurable cancer of the plasma cells. These cells-important parts of the immune system-normally make up a very small portion of the cells in the bone marrow, where they are made.
  ...
  "Patients are crucial to my research," explains Dr. Reiman.
  ...
  "RHAMM is a starting point for me to figure out what drives the biology of multiple myeloma, what distinguishes it from normal tissue," says Dr. Reiman. "In the end, it may be a protein other than RHAMM that is the key. My goal is to frame the research so that we can use the knowledge we gain in a way that helps patients."
  
  Dr. Tony Reiman is a medical oncologist at the Cross Cancer Institute and an assistant professor in the Department of Oncology at the University of Alberta. An AHFMR Clinical Investigator, he is also supported by CIHR (Canadian Institutes of Health Research), the National Cancer Institute of Canada, the Lance Armstrong Foundation, and the Alberta Cancer Board.
  
  For further information, please contact Dr Tony Reiman at (780) 432-8513 or tonyreim@cancerboard.ab.ca

• 
  Department of Oncology - Experimental Oncology Faculty - [Cached Version]
  Published on: 11/21/2008    Last Visited: 11/21/2008  

  Dr. Tony Reiman, MD, FRCP(C) Multiple Myeloma, Lymphoma, Lung Cancer - Patient Care, Clinical and Translational Research

• 
  Department of Oncology - Faculty Member - [Cached Version]
  Published on: 3/4/2009    Last Visited: 3/4/2009  

  Dr. Tony Reiman Department of Oncology - Faculty Member

• 
  Department of Oncology - Faculty Member - [Cached Version]
  Published on: 4/17/2006    Last Visited: 11/10/2008  

  Dr. Tony Reiman, MD, FRCP(C)Department of Oncology - Faculty Member
  ...
  Dr. Tony Reiman, MD, FRCP(C)
  ...
  Dr. Tony Reiman, MD, FRCP(C)Department of Medical OncologyRoom 2229, Cross Cancer Institute11560 University AvenueEdmonton, AB T6G 1Z2CANADA
  
  Phone:
  ...
  Vallance, J.K.H., Courneya, K.S., Jones, L.W., Reiman, T. Differences in quality of life between non-Hodgkin's lymphoma survivors meeting and not meeting public health exercise guidelines.

Page:  1 2